(Alliance News) - Nanoco Group PLC on Monday said it has ended the sale process that has run for over a year without producing a deal, with its chief executive departing next month as the company plans to cut costs and invest internally. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
(Alliance News) - Kavango Resources PLC on Monday said drilling at a gold mine in Zimbabwe exceeded expectations, underpinning its longer-term potential. Read More
(Alliance News) - Hundreds of British hospitality businesses shut their doors for good in the final months of 2025, as they warned over further tax hikes following the autumn budget. Read More
(Alliance News) - Stock prices in London opened mixed on Monday, with the FTSE 100 edging lower as a rally against the dollar and strength in metals-related stocks shaped early trade, while investors look ahead to a heavy week of Big Tech earnings. Read More
(Alliance News) - Costain Group PLC on Monday said a new agreement with the trustees of its defined-benefit pension scheme has cleared the way for increase shareholder returns, including a GBP20 million share buyback this year. Read More
(Alliance News) - Grainger PLC on Monday announced a scheme that it said will "further strengthen" its London portfolio. Read More
(Alliance News) - S4 Capital PLC on Monday said 2025 trading was ahead of revised guidance issued in November, and above the current consensus, although it stressed there is "still much more to be done." Read More
(Alliance News) - GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. Read More
(Alliance News) - Pan African Resources PLC on Monday declared a maiden interim dividend after delivering robust production, positioning the junior gold producer to post "outstanding" full-year financial results. Read More
(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More
Eco Atlantic Oil & Gas Ltd - Atlantic margin-focused oil and gas explorer with offshore license interests in Guyana, Namibia and South Africa - Raises USD10 million from subscriptions to 26.9 million new shares at 27.5 pence per share. The new shares will represent 7.9% of the enlarged total. Each new share comes with a warrant for an additional share at 40p, exercisable over the next three years. Eco enters binding agreements with Israel-based institutional investors for the new shares. The fresh funds will be used geological and geophysical work at Eco's licenses in Guyana, Namibia and South Africa. "We are delighted to welcome a number of leading Israeli institutional investors to our share register through this USD10 million direct subscription," comments Eco Chief Executive Officer Gil Holzman. "Their participation and long-term commitment represents a strong endorsement of the quality of our Atlantic Margin portfolio, our exploration and value-creation strategy, and our disciplined, capital-efficient approach." Read More
Shuka Minerals PLC - Africa-focused mine operator and developer - Issues 2.76 million new shares to Gathoni Muchai Investments Ltd. These will settle 3% establishment fee linked to the unsecured loan signed in June last year, and historic fees related to Gathoni Muchai's consultancy agreement. To date, GBP1.12 million has been drawn down under the Gathoni Muchai loan, with a further GBP385,000 remaining undrawn. Read More
Genus PLC - Basingstoke, England-based animal biotechnology and genetics - Says government approves the use of its gene edit for pigs, which provides resistance to a global disease. Porcine reproductive and respiratory syndrome causes suffering and premature death to pigs, with Genus noting a study that estimated the cost of PRRS at USD1.2 billion per year in the US alone. The approval of the PRRS resistant pig programme follows years of work with multiple Canadian regulators, Genus says, and is an important step toward commercialisation in North America. Genus is seeking approval for the PRP gene edit in key North American export markets such as Mexico and Japan, as well as in China. Read More
(Alliance News) - Stocks in London are set to open slightly higher on Monday, as Europe wakes up to sharp moves across commodity and foreign exchange markets. Read More